Logo image
Nuclear Imaging of Neuroendocrine Tumors
Journal article   Open access   Peer reviewed

Nuclear Imaging of Neuroendocrine Tumors

Janet Pollard, Parren McNeely and Yusuf Menda
Surgical oncology clinics of North America, Vol.29(2), pp.209-221
04/01/2020
DOI: 10.1016/j.soc.2019.11.007
PMCID: PMC7700750
PMID: 32151356
url
https://www.ncbi.nlm.nih.gov/pmc/articles/7700750View
Open Access

Abstract

Consensus guidelines acknowledge the role of gallium Ga-68 (Ga-68) 1,4,7,10-tetraazacyclododecane-N,N',N '',N'''-tetraacetic (DOTA) somatostatin receptor (SSTR) positron emission tomography/computed tomography (PET/CT) in management of neuroendocrine tumor (NET) patients. Ga-68-DOTA-SSTR PET/CT demonstrates superior performance to conventional imaging in initial detection, staging, detection of recurrent tumor, and detection of unknown primary in known metastatic disease. Ga-68-DOTA-SSTR PET/CT is low yield for NET detection in the setting of symptoms or elevated biomarkers when conventional imaging is negative, but may still guide management. The role of Ga-68-DOTA-SSTR PET/CT is not established in monitoring response to systemic therapy but may identify progression through detection of new metastases.
Life Sciences & Biomedicine Oncology Science & Technology Surgery

Details

Metrics

Logo image